Tanda M, Yamamoto K, Hori T, Nishiguchi H, et al. Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients. Anticancer Res 2023;43:1775-1783.
PMID: 36974789